Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumato...
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
About this item
Full title
Author / Creator
Publisher
England: EULAR
Journal title
Language
English
Formats
Publication information
Publisher
England: EULAR
Subjects
More information
Scope and Contents
Contents
ObjectiveTofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA.MethodsData were pooled for patients with RA who received...
Alternative Titles
Full title
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_06d315c88fb8416d89479fa698afb87f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_06d315c88fb8416d89479fa698afb87f
Other Identifiers
ISSN
2056-5933
E-ISSN
2056-5933
DOI
10.1136/rmdopen-2020-001395
